Oncopeptides Past Earnings Performance
Past criteria checks 0/6
Oncopeptides has been growing earnings at an average annual rate of 6.5%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 29.7% per year.
Key information
6.5%
Earnings growth rate
16.1%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 29.7% |
| Return on equity | -438.7% |
| Net Margin | -707.3% |
| Next Earnings Update | 30 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Oncopeptides makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 35 | -249 | 188 | 107 |
| 30 Sep 23 | 30 | -259 | 178 | 131 |
| 30 Jun 23 | 27 | -307 | 178 | 175 |
| 31 Mar 23 | 9 | -310 | 154 | 182 |
| 31 Dec 22 | 8 | -338 | 142 | 218 |
| 30 Sep 22 | -14 | -641 | 304 | 345 |
| 30 Jun 22 | 41 | -1,330 | 464 | 444 |
| 31 Mar 22 | 99 | -1,294 | 681 | 567 |
| 31 Dec 21 | 118 | -1,430 | 874 | 680 |
| 30 Sep 21 | 140 | -1,549 | 907 | 727 |
| 30 Jun 21 | 86 | -1,155 | 889 | 771 |
| 31 Mar 21 | 19 | -1,532 | 788 | 831 |
| 31 Dec 20 | 0 | -1,595 | 654 | 866 |
| 30 Sep 20 | 0 | -1,327 | 494 | 792 |
| 30 Jun 20 | 0 | -1,133 | 364 | 750 |
| 31 Mar 20 | 0 | -904 | 262 | 655 |
| 31 Dec 19 | 0 | -741 | 199 | 548 |
| 30 Sep 19 | 0 | -608 | 146 | 482 |
| 30 Jun 19 | 0 | -512 | 116 | 399 |
| 31 Mar 19 | 0 | -485 | 124 | 366 |
| 31 Dec 18 | 0 | -411 | 106 | 314 |
| 30 Sep 18 | 0 | -368 | 100 | 276 |
| 30 Jun 18 | 0 | -325 | 80 | 255 |
| 31 Mar 18 | 0 | -248 | 47 | 205 |
| 31 Dec 17 | 0 | -250 | 50 | 198 |
| 30 Sep 17 | 0 | -243 | 52 | 180 |
| 30 Jun 17 | 0 | -216 | 53 | 152 |
| 31 Mar 17 | 0 | -172 | 38 | 124 |
| 31 Dec 16 | 0 | -125 | 25 | 90 |
| 31 Dec 15 | 0 | -62 | 10 | 44 |
Quality Earnings: 0RN4 is currently unprofitable.
Growing Profit Margin: 0RN4 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0RN4 is unprofitable, but has reduced losses over the past 5 years at a rate of 6.5% per year.
Accelerating Growth: Unable to compare 0RN4's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0RN4 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 0RN4 has a negative Return on Equity (-438.73%), as it is currently unprofitable.